Total expenses increased 6% to Rs 1,197.90 crore in Q4 FY25 as against Rs 1,130.10 crore posted in same quarter last year. Cost of material consumed stood at Rs 186.68 crore (up 15.38% YoY), employee benefit expense was at Rs 144.40 crore (down 0.58% YoY) and finance cost was at Rs 3.92 crore (up 39.5% YoY) during the period under review.
On full year basis, the company’s standalone net profit jumped 17.8% to Rs 1,414.44 crore on a 9.6% rise in revenue from operations to Rs 6,409.15 crore in FY25 over FY24.
Meanwhile, the company’s board recommended payment of final dividend of Rs 475 per equity share of Rs 10 each for FY25, subject to approval of shareholders at the ensuing Eighty-first annual general meeting of the company scheduled to be held on Wednesday, August 13, 2025. The company has fixed the record date as Friday, 25 July 2025.
The aforesaid final dividend, if approved by the members, will be paid on or after Monday, August 18, 2025.
Abbott India is a subsidiary of Abbott Laboratories, headquartered in Mumbai. The company provides products and solutions across various therapeutic areas including gastroenterology, women’s health, metabolics, central nervous system, vaccines and multi-specialty.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."